American medicine is brilliant at miracles and strangely bad at receipts. A surgeon can replace a knee, a pharmacist can explain a medication with the patience of a kindergarten teacher on picture day, and a primary care doctor can spot trouble in a ten-minute visit. Then the bill arrives, and suddenly everyone needs a treasure map, a translator, and perhaps a small legal team.

The problem is not that every middleman in healthcare is useless. Insurance plans, pharmacy benefit managers, claims processors, care coordinators, billing systems, and administrators can serve real functions. The problem is the middleman mentality: the idea that healthcare becomes “better” by adding another approval gate, another pricing layer, another opaque contract, another portal password, another entity that collects a fee before care reaches the patient.

In theory, these players are supposed to organize chaos. In practice, too many have learned to profit from chaos. The result is a healthcare system where patients are treated as paperwork, doctors become unpaid data-entry clerks, pharmacies fight invisible pricing rules, and employers pay more every year while getting a benefits package that requires a decoder ring.

What Is the Middleman Mentality in Healthcare?

The middleman mentality is a business approach that thrives between the person who needs care and the person who provides it. It does not always create better medicine. It creates checkpoints. It creates leverage. It creates delay. Most importantly, it creates opportunities to collect money from transactions that patients do not understand and often cannot avoid.

In American medicine, middlemen include health insurers, pharmacy benefit managers, third-party administrators, claims clearinghouses, utilization review companies, group purchasing organizations, revenue-cycle vendors, referral networks, and data platforms. Some are necessary. Many do useful work. But when the system rewards complexity more than clarity, the middleman stops being a helper and becomes a tollbooth.

Think of it this way: if healthcare were a restaurant, the doctor would cook the meal, the patient would eat it, and the bill would be clear. American healthcare adds a menu consultant, a napkin utilization manager, a sauce preauthorization vendor, a rebate negotiator, and a company that denies your fork because you did not prove “medical necessity.” Delicious? Not exactly.

The Numbers Tell a Painful Story

The United States spends more on healthcare than any other high-income country, yet Americans do not consistently get better outcomes for that money. National health expenditures reached about $5.3 trillion in 2024, or more than $15,000 per person. Healthcare consumed roughly 18 percent of the country’s gross domestic product. That is not a healthcare sector; that is an economic weather system.

For families, the pressure is immediate. Employer-sponsored insurance premiums have continued climbing, with family coverage approaching the cost of a small car every year. Deductibles have also risen over time, meaning many insured Americans still hesitate before seeing a doctor because “insured” does not always mean “affordable.” It often means “you may now begin your financial obstacle course.”

Administrative spending is a major part of the story. Billing, coding, eligibility checks, claim edits, prior authorization, payment appeals, network management, and contract disputes consume money and human energy before anyone’s blood pressure is checked. Every form has a cost. Every denial has a cost. Every hour a nurse spends arguing with a portal is an hour not spent helping a patient.

Pharmacy Benefit Managers: The Middlemen Everyone Is Finally Watching

Pharmacy benefit managers, or PBMs, were originally created to help health plans manage prescription drug benefits. They negotiate with drug manufacturers, build formularies, process pharmacy claims, and set reimbursement terms. In a clean system, PBMs would help lower drug costs. In the real system, their incentives can become murky enough to make a swamp look transparent.

The largest PBMs control a huge share of prescription drug claims. They sit between drug manufacturers, insurers, employers, pharmacies, and patients. They negotiate rebates and discounts, but patients do not always see those savings at the pharmacy counter. In some arrangements, higher list prices can produce larger rebates, which may help a plan sponsor on paper while leaving a patient with an ugly copay at the counter.

This is why insulin, cancer drugs, heart medications, and specialty generics have become central examples in the debate. Patients hear that “discounts were negotiated,” yet their wallet experiences the opposite. Independent pharmacies also complain that reimbursement formulas can make it difficult to stay open, especially in rural communities where the local pharmacy may be the closest healthcare access point for miles.

The PBM debate is not simple. Drug manufacturers set list prices. Insurers design benefits. Employers choose plans. Pharmacies operate under contracts. But PBMs are powerful because they influence which drugs are covered, how much pharmacies are paid, how rebates flow, and which patients face barriers. When one middleman controls the maze, it is fair to ask whether the maze is there for savings or for strategy.

Prior Authorization: The Art of Delaying the Obvious

Prior authorization is another famous child of the middleman mentality. The concept sounds reasonable: before paying for expensive tests, procedures, or medications, insurers want confirmation that the care is appropriate. Nobody wants wasteful medicine. Nobody wants unnecessary scans. Nobody wants a system where every sore elbow gets a luxury MRI and a commemorative tote bag.

But prior authorization has expanded far beyond common-sense review. Doctors and patients now face approval requirements for imaging, medications, surgeries, rehabilitation, home care, and sometimes routine treatments. The process can delay care, increase anxiety, and bury medical offices in forms. A physician may know what a patient needs, but the treatment can still sit behind a digital gate guarded by a fax machine from 1998.

The harm is not merely inconvenience. A delayed medication can mean worsening symptoms. A delayed scan can mean a later diagnosis. A delayed discharge plan can mean a longer hospital stay. For patients with chronic illness, prior authorization can turn every refill into a suspense thriller: “Will I get my medication this month, or will I spend Tuesday on hold listening to flute music?”

Federal regulators have pushed for electronic prior authorization, shorter decision timelines, better data sharing, and more transparency. Those reforms matter. But the deeper question remains: why is so much clinical judgment being second-guessed by entities that often do not see the patient, examine the patient, or live with the consequences of delay?

How Middlemen Turn Price Into a Magic Trick

American healthcare prices are famously difficult to understand. A hospital may have a list price, a negotiated insurer price, a cash price, a patient responsibility estimate, and a final bill that arrives weeks later wearing a fake mustache. Price transparency rules have forced hospitals and insurers to publish more data, but data alone does not equal clarity.

Middlemen thrive when prices are hidden, fragmented, or negotiable only by insiders. The patient rarely knows the true cost before care. The doctor often does not know what a patient’s plan will pay. The employer may not fully understand the contract. The insurer may blame the provider. The provider may blame the insurer. Everyone points across the room while the patient stands in the middle holding a bill the size of a beach towel.

This opacity is not an accident. Complex pricing creates leverage. It allows different parties to claim savings, discounts, network value, and “allowed amounts” without giving patients a simple answer to the question: “What will this cost me?” In most industries, a customer can compare prices before buying. In healthcare, people often compare prices after the service, during a mild panic attack.

The Human Cost: Doctors Burn Out, Patients Give Up

The middleman mentality does not only inflate dollars. It drains trust. Patients begin to suspect that every denial is a tactic. Doctors begin to feel that the system doubts their judgment by default. Nurses, pharmacists, and office staff spend hours solving administrative puzzles that would make a tax accountant blink twice.

Burnout is not just about long hours. It is about moral injury: knowing what a patient needs, then watching a nonclinical process delay or block it. A doctor who spends the evening appealing a denial is not doing “paperwork.” That doctor is fighting a system that has placed bureaucracy between knowledge and action.

Patients experience their own version of burnout. They postpone care because the bill is unpredictable. They skip medications because the copay jumps. They abandon appointments because the referral process feels impossible. They lose faith because healthcare begins to feel less like a healing profession and more like a subscription service with surprise penalties.

Specific Examples of the Middleman Problem

1. The Patient Who Has Insurance but Cannot Use It

A patient pays premiums every month, chooses an in-network doctor, and finally schedules a needed scan. Then the insurer requires prior authorization. The doctor submits records. The request is denied. The office appeals. The patient waits. The scan eventually gets approved, but weeks have passed. The insurer may say the process prevents waste. The patient experiences it as paid coverage hiding behind a locked door.

2. The Pharmacist Caught Between Contracts

An independent pharmacist wants to fill prescriptions and counsel patients. Instead, the pharmacy must navigate reimbursement rules, clawbacks, preferred networks, and audit risks. Sometimes the payment for a drug may not cover acquisition cost. The patient asks why the price is so high. The pharmacist may not be allowed to fully explain the contract terms. Everyone is frustrated except the spreadsheet.

3. The Employer Buying Benefits in the Fog

Employers sponsor coverage for millions of Americans, but many struggle to see exactly where the money goes. A benefits package can include insurer fees, PBM arrangements, network access charges, consulting costs, stop-loss coverage, and rebate flows. Even a well-meaning employer may be buying healthcare through a foggy windshield. When costs rise, workers often absorb the pain through higher premiums, deductibles, or narrower choices.

Why “More Management” Does Not Always Mean Better Care

Healthcare absolutely needs management. Complex systems require coordination, fraud prevention, safety checks, and quality measurement. The question is not whether healthcare should be managed. The question is whether management has become detached from care.

When management improves outcomes, it is valuable. When it reduces duplicate testing, catches dangerous drug interactions, or helps a patient transition safely from hospital to home, it earns its place. But when management simply creates friction, extracts fees, or shifts costs in ways patients cannot see, it becomes a parasite wearing a lanyard.

The best healthcare systems simplify the path from need to treatment. The American system often adds lanes, tolls, gates, exits, and warning signs. Then it congratulates itself for building a bigger road.

What Reform Should Look Like

Fixing the middleman problem does not mean abolishing every intermediary. It means forcing every intermediary to prove value. If a company stands between patient and care, it should have to answer three questions: Does it reduce total cost? Does it improve outcomes? Does it make care easier to access?

First, drug pricing needs real transparency. Rebates, spread pricing, pharmacy reimbursement, and formulary incentives should be visible to plan sponsors and regulators. Savings should reach patients at the point of sale, especially for drugs people need to survive.

Second, prior authorization should be limited, fast, electronic, and accountable. Plans should publish denial rates, approval times, appeal outcomes, and the clinical basis for decisions. Repeatedly approved therapies for stable chronic conditions should not require endless reapproval. A patient with diabetes should not have to annually prove that diabetes did not wander off over the summer.

Third, price transparency must become usable. Posting giant machine-readable files is a start, but patients need clear estimates before care. Employers need access to claims and contract data. Doctors need cost information inside clinical workflows. Transparency should not require a data science degree and a heroic tolerance for spreadsheets.

Fourth, administrative simplification should be treated as patient safety. Every unnecessary form is a small delay. Every delay can become harm. Standardized electronic transactions, cleaner eligibility checks, automatic renewal for chronic therapies, and simplified appeals could save billions while giving clinicians time back.

Finally, healthcare policy should reward direct value instead of strategic complexity. The system should pay for better care, fair prices, faster access, and improved outcomes. It should not reward entities merely because they are positioned between money and medicine.

Conclusion: Medicine Needs Fewer Tollbooths

The middleman mentality is killing American medicine because it changes the mission. Healthcare should begin with the patient and organize around healing. Too often, it begins with contracts and organizes around control.

American medicine does not lack talent. It has world-class clinicians, researchers, hospitals, pharmacies, and innovators. What it lacks is simplicity. The country has built a system where too many players can make money from confusion, delay, and opacity. That is not sustainable. It is not ethical. It is also deeply annoying, which is not a technical policy term but should be.

The future of American healthcare depends on a basic reset: fewer tollbooths, clearer prices, faster approvals, honest drug costs, and middlemen who earn their keep. If an intermediary truly adds value, keep it. If it only adds friction, shrink it. If it profits from patients not understanding the system, expose it.

Medicine should not feel like a negotiation with a locked vending machine. It should feel like care. Until America remembers that, the middleman mentality will keep draining money, trust, and time from the people the system exists to serve.

If U.S. health care were a group project, insurance companies would be the classmate who says,
“I’ll just review your draft,” and then rewrites half your paper, changes your font, and asks if
your bibliography is “medically necessary.” That sounds dramatic, but patients and clinicians feel
this every day: care decisions that seem to happen not only in exam rooms, but also in payer portals,
utilization review queues, and appeal workflows.

So how did this happen? Not in one grand villain speech. It happened graduallythrough policy choices,
payment design, employer benefit structures, legal guardrails, and real concerns about wasteful care.
The result is a system where insurers are no longer just paying claims after treatment. In many cases,
they influence what treatment gets approved, when, and under which conditions.

The short answer: we built a system that rewards gatekeeping

America did not design a single national insurance model. Instead, it layered public programs, employer plans,
and private insurance markets on top of one another. That patchwork needed “traffic control,” and utilization
management became the control tower. Prior authorization, step therapy, network design, and medical-necessity
criteria all expanded as cost-control tools.

In plain English: as prices rose and treatment options multiplied, payers were given more authority to verify
whether care met coverage rules before they paid. Over time, “verify and pay” drifted into “approve before care,”
which feels very different when you’re waiting for surgery, imaging, or medication.

How we got here: the policy timeline nobody reads for fun (but should)

1) Job-based coverage became the backbone

U.S. insurance grew around employers, then stayed there because tax policy made it attractive.
That design tied coverage to work, outsourced plan administration, and normalized third-party review
between doctor and payment.

2) Managed care turned insurers into utilization managers

As spending climbed, insurers adopted tools intended to reduce unnecessary care and control costs.
Some methods were sensible. Others became blunt instruments. What began as guardrails often became speed bumps,
and sometimes roadblocks.

3) Legal structure limited who could regulate what

Federal law (especially for many self-funded employer plans) narrowed how much states could intervene.
So consumer protections became uneven: strong in one market segment, weak in another, confusing almost everywhere.

4) Digital workflows scaled payer influence

Once authorization systems moved into electronic platforms, they became easier to standardize and expand.
That can improve consistencybut it can also turn nuanced clinical judgment into checkbox logic.

What the current data says about insurer involvement

Recent federal rules now require faster prior authorization decisions for many plans (urgent requests generally
within 72 hours and standard requests within seven days), plus clearer denial reasons and better data exchange.
That reform itself tells a story: prior auth became so central that policymakers had to regulate the mechanics.

Large physician surveys continue to report substantial administrative burden and frequent care delays associated
with prior authorization. Meanwhile, patient polling shows prior authorization is now one of the most visible
pain points in navigating careeven beyond raw costs.

Federal audits also found that some denied requests in Medicare Advantage and Medicaid managed care should have
been approved under program rules. Appeals data often shows that when patients do appeal denials, a meaningful
share of decisions are later reversed. Translation: the first answer is not always the right answer.

To be fair: why insurers defend this role

If we’re being honest, insurers are not wrong about everything. They argue that utilization management helps:

• reduce low-value or duplicative care,
• improve patient safety (for example, inappropriate prescribing risks),
• keep premiums from rising even faster, and
• promote evidence-based pathways.

Industry groups also point out that many requests are approved and that not all services require prior authorization.
Those points matter. But they don’t erase the lived reality that delays and denials can derail treatment timing,
increase stress, and shift hidden administrative labor onto clinics and families.

Why this feels so personal to patients

Timing mismatch

Illness works in real time. Authorization often works in business time. Even short delays can trigger worse symptoms,
extra appointments, or avoidable emergency care.

Language mismatch

Clinicians think in diagnosis and outcomes. Payers think in benefit design, coding logic, and criteria. Patients are
stuck translating both, often while sick.

Accountability mismatch

Doctors carry ethical duty for outcomes. Insurers carry fiduciary duty for cost and policy compliance. When those
priorities collide, the patient experiences it as conflict inside their care plan.

Power mismatch

A patient can barely decode an Explanation of Benefits, much less mount a legally precise appeal while managing pain,
fatigue, or a new diagnosis. The process rewards organizations with time, staffing, and software.

How laws and market structure amplified insurer control

Employer plan complexity

Employer-sponsored insurance remains dominant for many Americans, and those plans vary wildly in design.
Different employers, administrators, pharmacy benefit structures, and provider contracts mean the “rules of care”
can change when you change jobsor even when your employer changes vendors.

ERISA preemption and uneven protections

Many self-funded employer plans are governed federally in ways that can limit state-level consumer protections.
That does not mean no protections exist; it means protections are fragmented, and enforcement paths are less intuitive
for ordinary people.

Medicare Advantage growth

As private plans cover more Medicare beneficiaries, prior authorization policy in that market has outsized effects.
Oversight has improved, but audits and policy revisions suggest persistent tension between utilization management
and timely access.

Administrative complexity as a business model byproduct

U.S. health care has exceptional administrative layering. Each layereligibility checks, coding edits, pre-service review,
network rules, post-payment auditsadds friction. Some friction prevents waste; too much friction becomes waste.

What should change now (without pretending cost control is optional)

1) Make authorization the exception, not the default

Require plans to publicly justify which services need prior authorization, with clinical evidence and periodic review.
If a service has high approval rates, remove it from prior auth lists.

2) Expand “gold card” programs carefully

Providers with strong approval histories should face fewer hoops, while guardrails remain for outlier billing patterns.
Reward high-quality ordering behavior with less bureaucracy.

3) Standardize and simplify appeals

One timeline, one language standard, one digital pathway, and plain-English denial explanations.
If an appeal overturn rate is high, that should trigger automatic scrutiny of the underlying rule.

4) Audit behavioral health and chronic-care denials aggressively

Conditions requiring continuity of care are most harmed by stop-start authorization barriers.
Oversight should focus where interruption costs are highest.

5) Align incentives around outcomes, not transaction volume

As long as revenue and margin are tied mostly to transaction complexity, complexity will reproduce itself.
Payment reform should reward improved outcomes and reduced avoidable friction.

6) Publish denial and overturn dashboards people can actually read

Transparency should be searchable, comparable, and understandable by patientsnot hidden in PDFs that require a decoder ring.

A practical playbook for patients and families

• Before treatment: ask if prior authorization is required and who submits it.
• At denial: request the exact denial reason, policy citation, and appeal deadline.
• For urgent cases: request expedited review and document clinical urgency.
• After reversal: verify claim reprocessing and patient cost-sharing correction.
• If employer coverage is involved: ask HR which plan type you have and where appeals escalate.

It is frustrating that this playbook exists at all. But until reform catches up, process literacy is a form of self-defense.
Not glamorous, not fair, but very effective.

from the front lines: experiences that explain the policy problem

Note: The following are composite scenarios built from common patterns reported by patients, clinicians, and care teams.

Maria, 47, had classic red-flag back symptoms and a specialist who wanted an MRI quickly. The clinic submitted prior authorization.
Two business days passed. Then three. Then a request came back for additional documentation that had already been uploaded in a different field.
The nurse resent it. The clock restarted. Maria did what millions of people do: she went to work anyway, took over-the-counter pain meds,
and hoped nothing serious was wrong. By the time approval arrived, she had spent nearly two weeks in escalating pain, missed shifts, and
started rationing groceries to save for out-of-pocket costs. The MRI eventually revealed a condition that needed intervention, and she got care.
But the emotional memory she keeps isn’t the treatmentit’s the waiting, the uncertainty, and the feeling that her body was “pending review.”

Dr. Patel runs a busy primary care clinic. He jokes that he now practices two specialties: family medicine and “portal navigation.”
He has staff whose full-time job is authorizations, denials, resubmissions, peer-to-peer scheduling, and appeals. Some days, that team spends
more time proving medical necessity than coordinating medical care. They have checklists, scripts, and sticky-note workflows that look like a
NASA launch sequence, except this launch is for insulin refills and imaging studies. Dr. Patel doesn’t oppose all utilization management.
He’s seen inappropriate prescribing and duplicative tests. What wears him down is when clinically straightforward requests get delayed for
procedural reasons, then approved after extra paperwork. “If the answer was yes,” he says, “why did we burn a week getting there?”

Lena cares for her teenage son, who has a chronic condition requiring periodic therapy and occasional medication adjustments.
Every few months, coverage details shift just enough to trigger another round of forms. She keeps a binder with lab reports,
specialist notes, call logs, and denial letters. She has become excellent at insurance vocabulary against her will. She can explain
formulary tiers, exception requests, and appeal clocks better than many professionals. What she can’t explain is why each approval feels temporary.
“We’re not asking for luxury care,” she says. “We’re asking for continuity.” Her son notices the stress; he apologizes for being “expensive,”
and she reminds him that needing care is not a moral failing.

James, 71, enrolled in a Medicare Advantage plan because it offered dental and lower upfront premiums.
After a hospitalization, he needed post-acute services that triggered prior authorization. The initial decision came back negative.
His daughter appealed with help from a social worker. The denial was overturned, and services were approved. They were gratefulbut also puzzled.
If the final clinical answer was approval, what exactly did the initial denial accomplish besides delay? James recovered, but the family learned
that successful appeals still carry costs: extra caregiver time, extra provider calls, extra anxiety, and delayed recovery momentum.

On the insurer side, a medical director describes the opposite fear: paying for low-value or unsafe care at scale.
“If we remove every check,” she says, “we could expose members to unnecessary procedures and everyone to higher premiums.”
She is not wrong. The core challenge is not whether oversight should existit is how to design oversight that catches true outliers
without turning ordinary patients into case files. Most people can accept guardrails. What they reject is a maze. The policy lesson from
these stories is simple: when the system is hard to navigate even for educated, persistent families with clinician support, it is effectively
inaccessible for everyone else.

Conclusion: We didn’t “let” this happen all at oncewe normalized it, one rule at a time

Insurance companies became deeply involved in patient care because the U.S. built a fragmented financing system that relies on payer-side
gatekeeping to control cost and variation. Some of that oversight is legitimate and necessary. But the current balance often asks patients
and clinicians to absorb excessive administrative risk just to reach the care that was likely to be approved anyway.

The path forward is not anti-insurance or anti-clinician. It is pro-clarity, pro-accountability, and pro-timely care:
fewer low-value barriers, faster decisions, transparent criteria, meaningful audits, and stronger rights when denials are wrong.
In other words, keep the guardrails, remove the maze.